Vertex Pharmaceuticals Incorporated (VRTX) stock price, chart and research
Vertex Pharmaceuticals Incorporated (VRTX) last traded at $537.79 at the close on November 16, 2026, down $0.81 (0.15%) on the day.
- Day range: $534.12 to $549.56
- 52-week range: $412.27 to $568.67
- Market cap: $136.35 billion
- P/E (trailing 12 months): 34.61
- Forward P/E: 27.00
- EPS (trailing 12 months): $15.54
- Dividend yield: 0.00%
- Volume: 1,199,173 shares
About Vertex Pharmaceuticals Incorporated
Sector: Healthcare; industry: Biotechnology; headquarters: United States; CEO: Dr. Reshma Kewalramani FASN, M.D.; 6,400 employees; listed since 1991-07-24.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small…
Financials
Revenue over the last 12 months was $12.95 billion, net income $3.98 billion, a profit margin of 30.7%. Revenue grew 10.5% from a year earlier.
Institutional owners of VRTX (13F)
Tracked managers holding VRTX in 13F filings for the quarter ending 2026-09-30:
- Dimensional Fund Advisors LP: $603.5 million, 0.11% of its portfolio (reduced)
ETFs that hold VRTX
- SPY: SPDR S&P 500 ETF
- QQQ: Invesco QQQ Trust
- XLV: Health Care Select Sector SPDR
- VUG: Vanguard Morningstar Growth ETF
- VOO: Vanguard S&P 500 ETF
- IVV: iShares Core S&P 500 ETF
- QUAL: iShares MSCI USA Quality Factor ETF
- VTI: Vanguard Total Stock Market
Research VRTX with LunaTerminal
- Interactive chart from one day to ten years, with volume, technicals and comparisons.
- Valuation, analyst ratings, dividends, earnings history and recent news.
- Ask LunaTerminal about VRTX: AI answers that cite dated data; no account needed for your first 300 credits
- 13F filings: which managers own what
- How advisors use LunaTerminal for market research
- What LunaTerminal does for financial advisors
Market data via Fear & Greed (feargreedflow.com); 13F holdings from SEC filings. Market data can be delayed; check dates before relying on a figure. Answers are research, not financial advice.